|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00034801 |
This is a research study comparing the safety and efficacy of two active study medications
Condition | Intervention | Phase |
Depression Schizophrenia Schizoaffective Disorder |
Drug: olanzapine Drug: ziprasidone |
Phase IV |
MedlinePlus related topics: | Depression Schizophrenia |
Drug Information available for: | Olanzapine Ziprasidone Ziprasidone hydrochloride Ziprasidone mesylate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 30 Study Locations |
Eli Lilly and Company |
Study ID Numbers: | 5529, F1D-US-HGJU |
First Received: | May 2, 2002 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00034801 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|